Trial Profile
Combination Therapy With Sitagliptin (DPP 4 Inhibitor) and Lansoprazole (PPI) Inhibitor) to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lansoprazole (Primary) ; Sitagliptin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Acronyms REPAIR-T1D
- 18 Aug 2017 Status changed from active, no longer recruiting to completed.
- 20 Sep 2013 Planned end date changed from 1 Apr 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 14 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.